Wegovy is only sold as a once-weekly injection — there is no Wegovy pill on the market as of 2026. The oral form of semaglutide (the same active ingredient in Wegovy) is sold as Rybelsus, but Rybelsus is FDA-approved only for type 2 diabetes, not weight management. This is a common source of confusion because both products use the same molecule, and you may see articles or telehealth ads that conflate the two.
What Wegovy Is
Wegovy is a brand name for semaglutide manufactured by Novo Nordisk and FDA-approved in 2021 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. In 2024, the FDA expanded the approval to include adolescents 12 and older with obesity, and added a cardiovascular risk reduction indication for adults with cardiovascular disease and obesity. Wegovy is sold exclusively as a once-weekly subcutaneous injection.
What Rybelsus Is
Rybelsus is a brand name for oral semaglutide also manufactured by Novo Nordisk and FDA-approved in 2019. It is the only FDA-approved oral GLP-1 receptor agonist. Rybelsus is approved only for the treatment of type 2 diabetes mellitus in adults, taken once daily as a tablet. It is not approved for weight loss, despite using the same active ingredient as Wegovy.
Why No Wegovy Pill
Two factors explain why there’s no oral Wegovy:
Higher doses needed for weight loss. Weight-loss doses of semaglutide are substantially higher than diabetes doses. Wegovy maintenance dose is 2.4 mg per week; Rybelsus tops out at 14 mg per day. Delivering enough oral semaglutide to match the weight-loss effect of injectable Wegovy requires significantly higher oral doses than those in Rybelsus.
Bioavailability challenges. Semaglutide is a peptide. Peptides are normally destroyed by stomach acid and digestive enzymes. Rybelsus solves this with a co-formulated absorption enhancer (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, or SNAC), which temporarily neutralizes stomach acid and allows some semaglutide to be absorbed intact. Even so, oral bioavailability is roughly 0.4-1% of the dose, requiring much larger oral doses than injection.
Novo Nordisk ran the OASIS phase 3 trial program testing higher-dose oral semaglutide (25 mg and 50 mg daily) for weight loss in adults without diabetes. Results published in 2023 showed meaningful weight reduction, but as of 2026 FDA approval for a higher-dose oral weight-loss formulation has not occurred. If approved, it would likely be marketed under a new brand name rather than as “oral Wegovy.”
Comparison Table
| Feature | Wegovy (injection) | Rybelsus (pill) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved indication | Weight loss, CV risk reduction | Type 2 diabetes |
| Dosing frequency | Once weekly | Once daily |
| Doses available | 0.25, 0.5, 1, 1.7, 2.4 mg | 3, 7, 14 mg |
| Approved for weight loss? | Yes | No |
| Special instructions | Inject in abdomen, thigh, or arm | Empty stomach, wait 30 min before food |
| List price (monthly) | ~$1,349 | ~$968 |
How Wegovy Injections Work
Wegovy is sold in a single-dose pen with a fixed dose preloaded. You do not need to draw up the medication. The injection is given subcutaneously (just under the skin) in the abdomen, thigh, or upper arm, once per week. The needle is short and most people report minimal pain.
Dosing follows a slow titration schedule to minimize gastrointestinal side effects:
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance)
Pens are stored in the refrigerator unopened; once in use, a pen can be at room temperature for up to 28 days. Always check the FDA-approved patient instructions for storage details.
How Rybelsus Pills Work
Rybelsus has strict dosing rules to ensure absorption:
- Take on an empty stomach
- Swallow whole with no more than 4 ounces (120 ml) of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
If you miss these rules, the SNAC absorption enhancer cannot do its job and the dose is mostly wasted. Compliance is the practical challenge with Rybelsus.
What If You Want an Oral Weight-Loss Drug?
As of 2026, no FDA-approved oral GLP-1 weight-loss drug exists. Options include:
- Wait for FDA approval of high-dose oral semaglutide (under review at Novo Nordisk)
- Other oral weight-loss drugs (Qsymia, Contrave, Plenity) — different mechanisms, varying efficacy
- Off-label Rybelsus use (lower efficacy than Wegovy doses, rarely insurance-covered for weight loss)
- Injectable Wegovy or Zepbound (FDA-approved for weight loss)
Discuss the trade-offs with your prescriber. For more on injectable weight-loss options, see our treatment hub.
The Bottom Line
Wegovy is injection-only — there is no Wegovy pill. The oral semaglutide pill (Rybelsus) is FDA-approved only for type 2 diabetes, not weight loss, even though it uses the same active ingredient. Trials of higher-dose oral semaglutide for weight loss are complete but not yet FDA-approved. If you want oral semaglutide for weight management, no FDA-approved option exists today; consult your prescriber about whether off-label Rybelsus, other oral weight-loss drugs, or injectable Wegovy or Zepbound fits your situation.
